USSTOCK.TODAY
Pre-Market
Log in Sign up

Sanofi and ScionX Bio enter strategic collaboration to develop mRNA therapeutics

Pharmaceutical Technology +1 ·

SNY Sanofi ADR
$41.40 +4.62%
View chart & analysis →
  1. 1Sanofi signed a global licensing and strategic collaboration agreement with ScionX Bio on October 21, 2026.
  2. 2ScionX Bio will directly lead the optimization program through the in vivo validation stage.
  3. 3Sanofi will be responsible for all subsequent preclinical research, clinical trials, manufacturing, and global commercialization.

So what's the key point?

Sanofi and ScionX Bio have agreed to work together to create new treatments. ScionX Bio will lead the research, while Sanofi will handle the later testing and sales.

Source Pharmaceutical Technology +1 · View original ↗

Related 3-line summaries

Regeneron's Dupixent drives Q2 results amid Eylea weakness The Motley Fool +1 · 3d agoNovartis shares rise 6% as remibrutinib meets MS Phase 3 goals Investopedia +2 · Sep 1Novartis Halts 8 CAR-T Trials After 3 Patient Deaths Barrons.com +1 · Sep 1
Today's 5 AI picks, all free
Nothing hidden: past picks and how they did against the S&P 500.
See today's picks →
← Back to news